Glenmede Trust’s Definium Therapeutics DFTX Stock Holding History

Glenmede Trust’s Portfolio DFTX Stock Details DFTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-1,439	Closed	-$13K	–	1312
2022 Q2	$13K	Hold	1,439	–	–	﹤0.01%	1247
2022 Q1	$23K	Buy	+1,439	New	+$25K	﹤0.01%	1265

Other funds holding DFTX

DCI

Data Collective IV Palo Alto, California $55.9M AUM 49.14% 1-Year Est. Return

MFG

Merit Financial Group Alpharetta, Georgia $16.4B AUM 25.17% 1-Year Est. Return

Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return

CVI Holdings Wilmington, Delaware $116M AUM 5.68% 1-Year Est. Return

Busey Bank Urbana, Illinois $3.68B AUM 26.6% 1-Year Est. Return

EAM

Empery Asset Management New York $83M AUM

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Telemetry Investments New York $63.3M AUM 0.06% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Group One Trading Chicago, Illinois $52.2B AUM 104.56% 1-Year Est. Return

Glenmede Trust's DFTX Position: Q3 2022 in Review

Glenmede Trust sold out of Definium Therapeutics (DFTX) in Q3 2022, closing a stake of 1,439 shares — an estimated $13K sold.

Glenmede Trust first reported a position in DFTX in Q1 2022 and held it in 2 quarters. The position peaked at $23K in Q1 2022. 101 funds tracked by Wall St. Rank hold DFTX as of Q3 2022.

Glenmede Trust reported no remaining Definium Therapeutics position as of Q3 2022 after selling out during the quarter.
Glenmede Trust sold 1,439 Definium Therapeutics shares in Q3 2022, an estimated $13K.
Glenmede Trust first reported a position in Definium Therapeutics in Q1 2022 and held it in 2 quarters.
Glenmede Trust's Definium Therapeutics position peaked at $23K in Q1 2022.
101 funds tracked by Wall St. Rank held Definium Therapeutics as of Q3 2022.

Based on Glenmede Trust's 13F filing for Q3 2022, filed 16 Nov 2022.